Maxion Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$89.2M
- Investors
-
9
Maxion Therapeutics General Information
Description
Developer of a novel platform designed to generate antibody-like therapeutics to solve ion channel- and GPCR-driven diseases. The company combines mini-proteins found in venom and other sources called knottins into the antibody surface to create mixtures while creating the optimum drug-like properties of antibodies, enabling patients with chronic pain, autoimmune, and cardiovascular diseases to access safe, long-lasting, and selective treatments.
Contact Information
Website
www.maxiontherapeutics.comCorporate Office
- C/O Mishcon De Reya, Africa House
- 70 Kingsway
- London WC2B 6AH
- England, United Kingdom
Corporate Office
- C/O Mishcon De Reya, Africa House
- 70 Kingsway
- London WC2B 6AH
- England, United Kingdom
Maxion Therapeutics Timeline
Maxion Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series A) | 15-Feb-2025 | $89.2M | Completed | Generating Revenue | ||
| 3. Grant | 19-Apr-2023 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 03-Feb-2023 | $15.9M | $15.9M | Completed | Generating Revenue | |
| 1. Grant | 01-Apr-2021 | $349K | Completed | Generating Revenue |
Maxion Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Series A | ||||||||
| Series A | 1,280,873 | $0.000124 | $11.87 | $11.87 | 1x | $11.87 | 16.34% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Maxion Therapeutics Comparisons
Industry
Financing
Details
Maxion Therapeutics Competitors (34)
One of Maxion Therapeutics’s 34 competitors is Entrinsic Bioscience, a Formerly VC-backed company based in Norwood, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Entrinsic Bioscience | Formerly VC-backed | Norwood, MA | ||||
| BioTheryx | Venture Capital-Backed | San Diego, CA | ||||
| Exo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Plexium | Venture Capital-Backed | San Diego, CA | ||||
| Enveda | Venture Capital-Backed | Boulder, CO |
Maxion Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Maxion Therapeutics Patents
Maxion Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202418438-D0 | Antigen binding proteins | Pending | 16-Dec-2024 | ||
| GB-202418439-D0 | Antigen binding proteins | Pending | 16-Dec-2024 | ||
| GB-202408483-D0 | Receptor agonists | Inactive | 13-Jun-2024 | ||
| WO-2025257333-A1 | Receptor agonists | Pending | 13-Jun-2024 | ||
| US-20230331827-A1 | Potassium channel inhibitors | Inactive | 12-Jul-2017 | C07K16/18 |
Maxion Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Maxion Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| British Business Bank | Lender/Debt Provider | Minority | ||
| British Patient Capital | Fund of Funds | Minority | ||
| General Catalyst | Venture Capital | Minority | ||
| Lilly USA | Corporation | Minority | ||
| Solasta Ventures | Venture Capital | Minority |
Maxion Therapeutics FAQs
-
When was Maxion Therapeutics founded?
Maxion Therapeutics was founded in 2020.
-
Where is Maxion Therapeutics headquartered?
Maxion Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Maxion Therapeutics?
Maxion Therapeutics has 50 total employees.
-
What industry is Maxion Therapeutics in?
Maxion Therapeutics’s primary industry is Drug Discovery.
-
Is Maxion Therapeutics a private or public company?
Maxion Therapeutics is a Private company.
-
What is the current valuation of Maxion Therapeutics?
The current valuation of Maxion Therapeutics is .
-
What is Maxion Therapeutics’s current revenue?
The current revenue for Maxion Therapeutics is .
-
How much funding has Maxion Therapeutics raised over time?
Maxion Therapeutics has raised $105M.
-
Who are Maxion Therapeutics’s investors?
British Business Bank, British Patient Capital, General Catalyst, Lilly USA, and Solasta Ventures are 5 of 9 investors who have invested in Maxion Therapeutics.
-
Who are Maxion Therapeutics’s competitors?
Entrinsic Bioscience, BioTheryx, Exo Therapeutics, Plexium, and Enveda are some of the 34 competitors of Maxion Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
